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Abstract Development of antimitotic binding to the
colchicine-binding site for the treatment of cancer is rapidly
expanding. Numerous antimicrotubule agents are prepared
every year, and the determination of their binding affinity to
tubulin requires the use of purified tubulins and radiolabeled
ligands. Such a procedure is costly and time-consuming and
therefore is limited to the most promising candidates. Here,
we report a quick and inexpensive method that requires only
usual laboratory resources to assess the binding of antimicro-
tubules to colchicine-binding site. The method is based on the
ability of N,N'-ethylene-bis(iodoacetamide) (EBI) to cross-
link in living cells the cysteine residues at position 239 and
354 of β-tubulin, residues which are involved in the
colchicine-binding site. The β-tubulin adduct formed by
EBI is easily detectable by Western blot as a second
immunoreacting band of β-tubulin that migrates faster than
β-tubulin. The occupancy of colchicine-binding site by
pertinent antimitotics inhibits the formation of the EBI: β-
tubulin adduct, resulting in an assay that allows the screening
of new molecules targeting this binding site.
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1 Introduction
Antimicrotubule agents are important in the management of
several cancers treatments notably breast, ovarian, and
lung. Unfortunately, their effect is often hampered by
chemoresistance, and they exhibit biopharmaceutical prop-
erties suitable for the treatment of only a limited number of
cancers [1]. New antimicrotubule agents are therefore
highly desirable, and several laboratories are eager to
develop new drugs exhibiting improved antitumor efficacy
and better biopharmaceutical properties [2]. One of the key
end-points used in the screening of new molecules, beside
the antiproliferative activity, is the binding affinity of the
drug to one or another of the specific binding sites present
on tubulin. Although binding sites for pironetin [3],
tryprostatin [4], epothilone [5], Vinca [6], Taxus [7], and
Colchicum [8] alkaloids have been identified so far, the
colchicine-binding site remains the main target of numerous
research programs. The determination and the characteriza-
tion of the binding site(s) for each and every newly
prepared drug to the latter binding sites are costly, time-
consuming, and require specialized equipment, highly
purified tubulin, and expensive radiolabeled ligands and
are therefore applied only to the most promising molecules.
To circumvent these limitations, we have developed an
inexpensive and simple detection technique to assess the
binding of antimicrotubule agents acting on the colchicine-
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binding site. This method is based on the property of N,N'-
ethylene-bis(iodoacetamide) (EBI), a homobifunctional thio-
alkylating agent, to crosslink the Cys-239 and the Cys-354
residues of β-tubulin involved in the colchicine-binding site
[9]. The covalent binding of EBI to β-tubulin forms an
adduct that is easily detected by Western blot as a second
immunoreacting band of β-tubulin that migrates faster than
the native β-tubulin band on SDS-PAGE (sodium dodecyl
sulphate (SDS) polyacrylamide gel electrophoresis) [10].
Luduena has used that property to characterize, in vitro, the
activity of several tubulin inhibitors [11, 12]. In the course of
our research program on 1-aryl-3-(2-chloroethyl)ureas [13],
we found that the incubation of colchicine and iodoaceta-
mide prevents the covalent binding of EBI in living cells
resulting in the disappearance of the second immunoreacting
band of β-tubulin on SDS-PAGE while vinblastine did not
prevent the covalent binding of EBI. That observation
provides us with a simple and inexpensive method to detect
quickly and directly on living cells the ability of a molecule
to bind to the colchicine-binding site without used of
purified tubulin and the expensive [3H]-colchicine. Further-
more, the study being performed on living cells, it provides
information on the ability of the drug to cross cell
membranes, to diffuse through the cytosol and to react with
dynamically functional microtubules that are in contact with
several cytoskeleton-associated proteins, information that are
unavailable when using only purified tubulins in a in vitro
setting.
In this study, we assessed the robustness of the method
using: (1) drugs binding to the three main binding sites found
on the α-,β-tubulin heterodimer, namely the taxol-, the
colchicine-, and the vinca-binding sites, (2) drugs unrelated
to tubulins and the cytoskeleton such as daunorubicin and
verapamil, and (3) four cell lines found in most laboratories.
As shown in Table 1, drugs binding to the colchicine-binding
site inhibit the bisthioalkylation of β-tubulin by EBI and
consequently the formation of the EBI: β-tubulin adduct and
the second immunoreacting β-tubulin band. Conversely,
vinca-binding site inhibitors and tubulin-unrelated drugs did
not inhibit the covalent binding of EBI and the formation of
Table 1 Competition assay of different drugs with N,N'-ethylene-bis(iodoacetamide) on MDA-MB-231 and their effects on the inhibition of the
bisthioalkylation of Cys-239 and Cys-354 of β-tubulin by N,N'-ethylene-bis(iodoacetamide)
Compound 
Cellular target 






(μM)   





















Paclitaxel + EBI β-Tubulin 
(T-BS) 
5 Yes 
Vinblastine + EBI β-Tubulin 
(vinca) 
5 No 
Vinorelbine + EBI β-Tubulin 
(vinca) 
100 No 




Daunorubicin + EBI Topoisomerase II 50 No 
N/A not applicable, C-BS colchicine-binding site, T-BS taxol-binding site
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the second immunoreacting β-tubulin band. Of note, the
distinct colchicine-binding site and the paclitaxel-binding site
are close (16–17Å) and share a slight overlap between their
interaction domains [14]. This overlap between the
colchicine-binding site and the paclitaxel-binding site seems
to explain the effect of paclitaxel when challenged by EBI, as
seen in Table 1 and may show a screening advantage for dual
inhibitors. In addition, as shown in Table 2, the assay can be
performed not only with MDA-MB-231 but also with cell
lines such as HT-29, M21, and MCF-7 that contain β-tubulin
isoforms bearing the Cys-239 and the Cys-354 residues.
As illustrated in Fig. 1, the inhibition of EBI binding to
tubulin is concentration-dependant. When the experiments
are performed using escalating concentrations of colchicine
and combretastatin A-4 (10 to 31 250-fold the IC50), a
semi-quantitative assessment of the affinity of the drug for
the binding site is possible. Moreover, the purity of the
sodium dodecyl sulfate (SDS) used to perform the experi-
ments is crucial, since SDS at 65% significantly improved
the separation between native β-tubulin and the EBI: β-
tubulin adduct.
2 Materials and Equipments
Human breast carcinoma MDA-MB-231, human colon
carcinoma HT-29, human skin melanoma M21, and human
breast carcinoma MCF-7 cells were obtained from the
American Type Culture Collection (ATCC HTB-26; Mana-
ssas, VA). Cells were grown in high glucose Dulbecco's
Modified Eagle Medium supplemented with 5% (v/v)
defined bovine calf serum (Hyclone laboratories, Logan,
UT). Cells were maintained in a moisture-saturated atmo-
sphere at 37°C in 5% of CO2. Biochemicals and the
monoclonal anti-β-tubulin antibody (clone TUB 2.1) were
purchased from Sigma-Aldrich (St. Louis, MO) and used as
received unless specified otherwise. SDS at 98.5% and SDS
at 65% of purity were purchased from Sigma-Aldrich. The
enhanced chemiluminescence Western blotting detection
reagent kit was provided by Amersham Canada (Oakville,
Canada). Mixtures are expressed as volume/volume ratios
unless indicated otherwise. Daunorubicin was purchased
from Rhône-Poulenc (Courbevoie, France) and combretas-
tatin A-4 was synthesized according to Petit et al. [15]. EBI
was obtained from TRC Biomedical Research Chemicals
(North York, ON, Canada). All drugs were dissolved in
dimethylsulfoxide, and the final concentration of dimethyl-
sulfoxide in the culture medium was maintained under 0.5%.
Table 2 Competition assay of different drugs with N,N'-ethylene-bis(iodoacetamide) on HT-29, M21, and MCF-7 and their effects on the










(μM) HT-29 M21 MCF-7  
Dimethylsulfoxide 0.5% 
   
N/A 
EBI 100 
   
N/A 
Colchicine + EBI 2.5 
   
Yes 
Combretastatin A-4 + 
EBI 
2.5 
   
Yes 
Podophyllotoxin + EBI 20 
   
Yes 
Daunorubicin + EBI 50 
   
No 
N/A not applicable
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3 Methods
3.1 Cell Culture and Treatment
Prior to drug exposition, 6-well plates were seeded with
either MDA-MB-231, HT-29, M21, or MCF-7 cells at 7×
105 cells per well and incubated for 24 h. Cells were first
incubated in presence of approximately 1,000-times the
IC50 of the drugs for 2 h and afterward treated with EBI
(100 μM, final concentration) for 1.5 h at 37°C without
changing the culture medium, which contains the drugs.
The control cells were treated with 0.5% dimethylsulfoxide.
Afterward, floating and adherent cells were harvested using
a rubber policeman and centrifuged for 3 min at 8,000 rpm.
The pellets were washed with 500 μL of cold phosphate-
buffered saline and stored at −80°C until use.
3.2 Western Blot
The cells pellets were lysed by addition of 100 μL of
Laemmli sample buffer 5× (60 mM Tris–Cl pH 6.8, 2%
SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bro-
mophenol blue). Cell extracts were boiled for 5 min. The
protein concentration was determined using the Bradford
method. Twenty micrograms of proteins from the protein
extracts were subjected to electrophoresis using 0.1% SDS
(98.5% or 65% of purity) and 10% polyacrylamide gels.
The proteins were transferred onto nitrocellulose mem-
branes that were incubated with TBSMT (Tris-buffered
saline + 0.1% (v/v) Tween-20 with 2.5% fat-free dry milk)
for 1 h at room temperature and then with the anti-β-
tubulin primary antibody in TBSMT (1:500) for 16 h at 4°C.
Membranes were washed with TBST (Tris-buffered saline
with + 0.1% (v/v) Tween-20) and incubated with
peroxidase-conjugated anti-mouse immunoglobulin in
TBSMT (1:2,500) for 2.5 h at room temperature. After
washing the membranes with TBST, detection of the
immunoblot was carried out with an enhanced chemilu-
minescence detection reagent kit.
4 Summarized Stepwise Protocol
1. Seeding 6-well plates with either MDA-MB-231, HT-
29, M21, or MCF-7 cells at 7×105 cells per well and
incubation for 24 h
2. Incubation of the cells for 2 h with the drug to be
tested and then with 100 μM of EBI for 1.5 h
3. Harvesting, pooling, and freezing of both floating and
adherent cells
4. Lysis of cells with Laemmli sample buffer and boiling
the samples for 5 min
5. Separation of the protein extracts by electrophoresis
using 10% polyacrylamide gels (100 V, 2.5 h)
6. Transfer of the proteins onto nitrocellulose membrane
(35 V, 16 h at 4°C)
7. Incubation of the nitrocellulose membrane with
TBSMT for 1 h
Fig. 1 Effect of escalating concentrations of combretastatin A-4 and
colchicine on the inhibition of the bisthioalkylation of Cys-239 and
Cys-354 of β-tubulin by N,N'-ethylene-bis(iodoacetamide) on MDA-
MB-231 cell lines. The experiments for panels A and B were
performed using SDS 65% while SDS 98.5% was used for panel C
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8. Incubation of the nitrocellulose membrane with the
primary antibody anti-β-tubulin for 16 h at 4°C then
washing five times with TBST
9. Incubation of the nitrocellulose membrane with the
peroxidase-conjugated anti-mouse immunoglobulin
for 2.5 h at room temperature and then washing five
times with TBST
10. Detection of β-tubulin bands using an enhanced
chemiluminescence detection reagent kit
5 Discussion of Key Steps in the Protocol
Concentration and duration of the incubation of the tested
drugwith the cells may change from one class of compound to
another. However, all drugs tested so far have produced good
signals when using the aforementioned experimental con-
ditions. The purity of the SDS used for the electrophoresis
seems critical for optimal separation of the β-tubulin and the
EBI: β-tubulin adduct. In our hand, the SDS at 65% of purity
supplied by Sigma-Aldrich was optimal (Fig. 1).
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